Trials
1 active
4 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Migraine
- Main trialPhase 2
- “This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.”In the company’s words, NCT07616128 on ClinicalTrials.gov
Other drugs for Migraine
- ElismetrepTriGemX Bio, Inc. · Tanabe Pharma Corporation · Phase 3
- UbrogepantAbbVie · Phase 3
- EptinezumabH. Lundbeck A/S · Phase 3
- BR005-036CBrise Pharmaceuticals Co., Ltd. · Phase 3
- AtogepantAbbVie · Phase 3
- ErenumabAmgen · Phase 3
Coming up1
- Oct 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Oct 2027 | Study of EVO756 in Adults With Migraine | |
| Phase 2Completed | 8 May 2025 | A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria | |
| Phase 2Completed | 29 May 2026 | Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU) | |
| Phase 2Completed | 23 Jul 2026 | Phase 2b Study of EVO756 in Adults With Atopic Dermatitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026